Amneal Pharmaceuticals, Inc. (AMRX)
Automate Your Wheel Strategy on AMRX
With Tiblio's Option Bot, you can configure your own wheel strategy including AMRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMRX
- Rev/Share 9.0987
- Book/Share -0.1909
- PB 2.2064
- Debt/Equity 2.5378
- CurrentRatio 1.404
- ROIC 0.0767
- MktCap 3356521828.0
- FreeCF/Share 0.7502
- PFCF 14.3831
- PE -171.8807
- Debt/Assets 0.7665
- DivYield 0
- ROE -0.069
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | AMRX | JP Morgan | Neutral | Overweight | $9 | $12 | Feb. 24, 2025 |
| Upgrade | AMRX | JP Morgan | Underweight | Neutral | -- | $9 | Sept. 6, 2024 |
News
3 Reasons Growth Investors Will Love Amneal (AMRX)
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Read More
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Here is Why Growth Investors Should Buy Amneal (AMRX) Now
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Read More
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript
Published: May 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder and Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Chris Schott - JPMorgan Operator Good morning and welcome to the Amneal Pharmaceuticals First Quarter 2025 Earnings Call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
Read More
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President and Chief Commercial Officer, Specialty Jason Daly - Chief Legal Officer Conference Call Participants Chris Schott - J.P. Morgan David Amsellem - Piper Sandler Leszek Sulewski - Truist Securities Balaji Prasad - Barclays Operator Good morning and welcome to the Amneal Pharmaceuticals Fourth Quarter 2024 …
Read More
Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock
Published: February 24, 2025 by: Benzinga
Sentiment: Positive
J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc AMRX, noting the company's generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfolio.
Read More
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
About Amneal Pharmaceuticals, Inc. (AMRX)
- IPO Date 2018-05-07
- Website https://www.amneal.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Chirag K. Patel
- Employees 8300